$7.00
Manufacturer: India
Treatment of such diseases in adults as: cryptococcal meningitis; coccidioidomycosis; invasive candidiasis; mucosal candidiasis, including oropharyngeal candidiasis and esophageal candidiasis; candiduria, chronic candidiasis of the skin and mucous membranes; chronic atrophic candidiasis (candidiasis caused by the use of dentures) when local dental hygiene products are ineffective; vaginal candidiasis, acute or recurrent when local therapy is inappropriate; Candida balanitis when local therapy is inappropriate; ringworm, including athlete’s foot, mycosis of a smooth skin, ringworm of the groin; multicolored lichen and Candida infections of the skin, when it is indicated to use systemic therapy; dermatophytic onychomycosis, when the use of other drugs is inappropriate.
Description
Fucis DT Storage
active substance: fluconazole;
1 tablet contains fluconazole 50 mg;
Excipients: lactose monohydrate, microcrystalline cellulose, povidone KZ0, talc, magnesium stearate, croscarmellose sodium, colloidal anhydrous silica, flavor “American ice cream DC 129” *, sodium saccharin.
* flavor “American ice cream DC 129” – lactose monohydrate, acacia (gum arabic) E 414, flavor identical to natural.
Fucis DT Dosage form
The tablets are dispersed.
Main physical and chemical properties: round white tablets with beveled edges, with a dividing line on one side and smooth on the other, with the smell of ice cream.
Fucis DT Pharmacotherapeutic group
Antifungal agents for systemic use. Triazole derivatives. ATX code J02A C01.
Pharmacological properties
Pharmacodynamics.
Fluconazole, an antifungal agent of the triazole class, is a potent selective inhibitor of fungal enzymes required for ergosterol synthesis. Its primary mechanism of action is the inhibition of fungal 14-alpha-lanosterol demethylation mediated by cytochrome P450, which is an integral step in the biosynthesis of fungal ergosterol. The accumulation of 14-alpha-methyl-sterols correlates with the subsequent loss of ergosterol by the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.
The use of fluconazole at a dose of 50 mg per day for 28 days does not affect the level of testosterone in plasma in men or the level of endogenous steroids in women of reproductive age. Fluconazole at a dose of 200-400 mg per day has no clinically significant effect on endogenous steroid levels or on the response to adrenocorticotropic hormone (ACTH) stimulation in healthy male volunteers.
Indication
Treatment of such diseases in adults:
cryptococcal meningitis;
coccidioidomycosis;
invasive candidiasis;
candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus; candidiasis, chronic candidiasis of the skin and mucous membranes;
chronic atrophic candidiasis (candidiasis caused by the use of dentures) with the ineffectiveness of local dental hygiene products;
vaginal candidiasis, acute or recurrent, when local therapy is inappropriate;
candidal balanitis, when local therapy is inappropriate;
dermatomycoses, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis; ringworm and candidal skin infections when systemic therapy is indicated;
dermatophytic onychomycosis, when the use of other drugs is inappropriate.
Recent Reviews